Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 4055 Tudor Centre Drive, Anchorage, AK 99508, USA.
J Clin Microbiol. 2011 Jan;49(1):138-43. doi: 10.1128/JCM.01238-10. Epub 2010 Nov 3.
The International Circumpolar Surveillance (ICS) Program was initiated in 1999 to conduct population-based surveillance for invasive pneumococcal disease in select regions of the Arctic. An interlaboratory quality control (QC) program for pneumococcal serotyping and antibiotic susceptibility testing was incorporated into ICS by reference laboratories in northern Canada (Laboratoire de Santé Publique du Québec [LSPQ] in Sainte-Anne de Bellevue, Québec; National Centre for Streptococcus [NCS] in Edmonton, Alberta) and Alaska (Arctic Investigations Program [AIP]). The World Health Organization's Collaborating Centre for Reference and Research on Pneumococci at the Statens Serum Institute (SSI) in Copenhagen, Denmark, joined the QC program in 2004. The Iceland Reference Laboratory (IRL) in Reykjavik, Iceland, joined the QC program in 2006, but due to small sample sizes, data from IRL are not included in this report. From 1999 through 2008, 190 isolates were distributed among four laboratories (AIP, NCS, LSPQ, and SSI). The overall serotype concordance was 95.8%, and the overall serogroup concordance was 97.4%. The overall modal MIC concordance for testing by broth microdilution (BMD) and agar dilution was >96% for all the antibiotics except erythromycin (92.1%) and clindamycin (89.5%). MIC comparisons between the Etest and BMD resulted in lower concordance for erythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorical concordance (susceptible, resistant) remained high at 98.6%, 89.1%, and 90.9%, respectively. Our data demonstrate a high degree of correlation of serotyping and antimicrobial susceptibility testing results between four participating laboratories.
国际极区监测（ICS）计划于 1999 年启动，旨在对北极地区的选定地区进行基于人群的侵袭性肺炎球菌病监测。北方参考实验室（魁北克省圣安妮德贝尔维尤的魁北克公共卫生实验室[LSPQ]；艾伯塔省埃德蒙顿的国家链球菌中心[NCS]）和阿拉斯加（北极调查计划[AIP]）将肺炎球菌血清分型和抗生素药敏试验的实验室间质量控制（QC）计划纳入 ICS。丹麦哥本哈根的世界卫生组织肺炎球菌参考和研究合作中心（Statens Serum Institute [SSI]）于 2004 年加入 QC 计划。冰岛雷克雅未克的冰岛参考实验室（IRL）于 2006 年加入 QC 计划，但由于样本量小，IRL 的数据未包含在本报告中。1999 年至 2008 年，190 株分离株分发给四个实验室（AIP、NCS、LSPQ 和 SSI）。总体血清型一致性为 95.8%，总体血清群一致性为 97.4%。除红霉素（92.1%）和克林霉素（89.5%）外，肉汤微量稀释（BMD）和琼脂稀释试验的所有抗生素的总体模式 MIC 一致性>96%。Etest 和 BMD 之间的 MIC 比较导致红霉素（73.9%）、克林霉素（65.5%）和甲氧苄啶-磺胺甲恶唑（80%）的一致性降低，但分类一致性（敏感、耐药）仍分别保持在 98.6%、89.1%和 90.9%。我们的数据表明，四个参与实验室之间的血清分型和抗菌药物敏感性测试结果具有高度相关性。
